Therapeutic drug monitoring in methadone maintenance: Choosing a matrix

Journal of Addictive Diseases

Volumn 20, Issue 2, 2001, Pages 55-73

  Moolchan, Eric T ^a   Umbricht, Annie ^a   Epstein, David ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Methadone maintenance; Opioid addiction; Pharmacokinetics

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; COCAINE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; METHADONE; NELFINAVIR; NICOTINE; OPIATE; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SEROTONIN ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; ZIDOVUDINE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; DRUG SALIVA LEVEL; DRUG URINE LEVEL; HUMAN; MAINTENANCE THERAPY; OPIATE ADDICTION; PH MEASUREMENT; SWEAT;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; LIVER; MALE; METHADONE; MIXED FUNCTION OXYGENASES; NARCOTICS; OPIOID-RELATED DISORDERS; SALIVA; SWEAT;

EID: 0034774885     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v20n02_05     Document Type: Article

References (96)

1. Methadone treatment and the acquired immunodeficiency syndrome epidemic
2. Methadone dosage and retention of patients in maintenance treatment
3. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs
4. Methadone dose and urine morphine
5. The relationship of methadone dose and other variables to outcomes of methadone maintenance
6. Immnological function in active heroin addicts and methadone-maintained former addicts: Observations and possible mechanisms
7. Issues in the clinical management of intravenous drug users with HIV infection
8. The effects of psychosocial services on substance abuse treatment
9. Phases of treatment: A practical approach to methadone maintenance treatment
10. Sustained cocaine abstinence in methadone maintenance patients through Voucher-based reinforcement therapy
11. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients
12. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients
13. Inadequate plasma concentrations in some high-dose methadone maintenance patients
14. Plasma level and symptom complaints in patients maintained on daily dosage of methadone hydrochloride
15. Methadone maintenance: Plasma levels and therapeutic outcome
16. The use of plasma levels to optimize methadone maintenance treatment
17. Steady-state pharmacokinetics of methadone in opioid addicts
18. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts
19. Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration response curves
20. Opioid analgesics and antagonists
21. The pharmacokinetics of methadone in healthy subjects and opiate users
22. Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the induction phase
23. Methadone plasma level: Sustained by a reservoir of drug in tissue
24. Methadone maintenance: Optimizing dosage by estimating plasma level
25. Opiate-ethanol interactions: Implications for the biological basis and treatment of combined addictive diseases
26. Methadone binding to human plasma proteins
27. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain
28. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of alpha 1-acid glycoprotein
29. Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding
30. Rifampin-induced methadone withdrawal
31. Craving despite extremely high methadone dosage
32. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships
33. Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4
34. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
35. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone
36. Population pharmacokinetics of methadone in opiate users: Characterization of time-dependent changes
37. Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics
38. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects
39. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone
40. Ultra-rapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
41. Gender differences in pharmacokinetics and pharmacodynamics
42. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting
43. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine
44. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors
45. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
46. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)
47. The effect of fluconazole on the clinical pharmacokinetics of methadone
48. Phenytoin-induced methadone withdrawal
49. Fluvoxamine-methadone interaction
50. Cimetidine inhibits the in vitro N-demethylation of methadone
51. Ling Wa Cimetidine may decrease opiate withdrawal symptoms in methadone patients
52. Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome
53. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations
54. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
55. Alcohol and opioids: Possible interactions of clinical importance
56. Medical complications in methadone patients
57. Methadone use in patients with chronic renal disease
58. Renal failure and treatment of a methadone maintenance patient
59. Effect of disease states on plasma protein binding of drugs
60. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma
61. Methadone plasma protein binding: Alterations in cancer and displacement from alpha 1-acid glycoprotein
62. The effect of pregnancy and lactation on the elimination of methadone in guinea pigs
63. The relationship between maternal and fetal plasma protein binding of methadone in the ewe during the third trimester
64. A comparison of morphine and methadone disposition in the maternal-fetal unit
65. Alterations in methadone metabolism during late pregnancy
66. Pharmacokinetics of methadone in methadone maintenance treatment: Characterization of therapeutic failures
67. Use of serum levels for optimizing doses in methadone maintenance treatment
68. AIDS - A strange disease of uncertain origins
69. Shooting galleries and HIV disease: Variations in places for injecting illicit drugs
70. Rapid measurement of plasma methadone in a clinical setting using florescence polization immunoassay
71. Sweat testing for heroin, cocaine, and metabolites
72. Sweat testing for heroin and metabolites in a heroin maintenance program
73. Detection of drug use in a methadone maintenance clinic: Sweat patches versus urine testing
74. Enantioselective analysis of methadone in sweat as monitored by liquid chromatography/ion spray-mass spectrometry
75. Application of saliva for drug monitoring. An in vivo model for transmembrane transport
76. Anticonvulsant level in saliva, serum, and cerebrospinal fluid
77. Drug concentration in saliva
78. Analysis of methadone and metabolites in biological fluids with gas chromatography-mass spectrometry
79. Effect of plasma protein binding on the uptake of methadone and diazepam in the isolated perfused rat lung
80. Saliva/plasma ratio of methadone and EDDP
81. The secretion of methadone and its major metabolite in the gastric juice of humans: Comparison with blood and salivary concentrations
82. The monitoring of saliva drug levels: Psychiatric applications
83. Methadone in saliva
84. Therapeutic drug monitoring in saliva
85. Disposition of methadone in methadone maintenance
86. A method for the confirmation and identification of drugs of misuse in urine using solid phase extraction and gas-liquid chromatography with mass spectrometry
87. Detection of drugs in saliva of impaired drivers
88. Implications of managed care for methadone treatment. Findings from five case studies in New York State
89. Pharmacological issues in elderly patients on methadone
90. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in methadone maintenance programs
91. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone
92. Methadone-disulfiram interaction during methadone maintenance
93. Adolescent heroin use: A review